Enantiomerically Pure 2-Methyltetrahydro-3-benzazepin-1-ols Selectively Blocking GluN2B Subunit Containing N-Methyl-d-aspartate Receptors

Journal of Medicinal Chemistry

Volumn 58, Issue 15, 2015, Pages 6293-6305

  Tewes, Bastian ^a   Frehland, Bastian ^a   Schepmann, Dirk ^a   Robaa, Dina ^b   Uengwetwanit, Tanaporn ^b   Gaube, Friedemann ^c   Winckler, Thomas ^c   Sippl, Wolfgang ^b   Wünsch, Bernhard ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (4 PHENYLBUTYL) 2,3,4,5 TETRAHYDRO 1H BENZAZEPINE 1,7 DIOL; 2 METHYL 3 (4 PHENYLBUTYL)TETRAHYDRO 3 BENZAZEPIN 1 OL; 2 METHYLTETRAHYDRO 3 BENAZEPIN 1 OL DERIVATIVE; DEXAMETHASONE; ELIPRODIL; GLUTAMATE RECEPTOR; GUANIDINE DERIVATIVE; HALOPERIDOL; IFENPRODIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; BENZAZEPINE DERIVATIVE; NR2B NMDA RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; ENERGY TRANSFER; MOLECULAR DOCKING; MOUSE; NONHUMAN; RECEPTOR AFFINITY; STEREOCHEMISTRY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

BENZAZEPINES; EXCITATORY AMINO ACID ANTAGONISTS; MOLECULAR DOCKING SIMULATION; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939203840     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00897     Document Type: Article

References (35)

1. Bräuner-Osborne, H.; Egebjerg, J.; Nielsen, E. O.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for glutamate receptors: design, and therapeutic potential J. Med. Chem. 2000, 43, 2609-2645 10.1021/jm000007r
2. Kew, J. N. C.; Kemp, J. A. Ionotropic and metabotropic glutamate receptor structure and pharmacology Psychopharmacology 2005, 179, 4-29 10.1007/s00213-005-2200-z
3. Paoletti, P.; Neyton, J. NMDA recptor subunits: function and pharmacology Curr. Opin. Pharmacol. 2007, 7, 39-47 10.1016/j.coph.2006.08.011
4. Lodge, D. The history of the pharmacology and cloning of ionotropic glutamate receptors and the development of idiosyncratic nomenclature Neuropharmacology 2009, 56, 6-21 10.1016/j.neuropharm.2008.08.006
5. Furukawa, H.; Singh, S. K.; Mancusso, R.; Gouaux, E. Subunit arrangement and function in NMDA receptors Nature 2005, 438, 185-192 10.1038/nature04089
6. Karakas, E.; Simorowski, N.; Furukawa, H. Subunit arragement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors Nature 2011, 475, 249-253 10.1038/nature10180
7. Mony, L.; Kew, J. N. C.; Gunthorpe, M. J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential Br. J. Pharmacol. 2009, 157, 1301-1317 10.1111/j.1476-5381.2009.00304.x
8. Paoletti, P.; Bellone, C.; Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease Nat. Rev. Neurosci. 2013, 14, 383-400 10.1038/nrn3504
9. Layton, M. E.; Kelly, M. J., III; Rodzinak, K. J. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists Curr. Top. Med. Chem. 2006, 6, 697-709 10.2174/156802606776894447
10. Wu, L.-J.; Zhou, M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain Neurotherapeutics 2009, 6, 693-702 10.1016/j.nurt.2009.07.008
11. Williams, K. Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action Curr. Drug Targets 2001, 2, 285-298 10.2174/1389450013348489
12. Falck, E.; Begrow, F.; Verspohl, E.; Wünsch, B. Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist J. Pharm. Biomed. Anal. 2014, 88, 96-105 10.1016/j.jpba.2013.08.014
13. Borza, I.; Domány, G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore Curr. Top. Med. Chem. 2006, 6, 687-695 10.2174/156802606776894456
14. Yurkewicz, L.; Weaver, J.; Bullock, M. R.; Marshall, L. F. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury J. Neurotrauma 2005, 22 (12) 1428-1443 10.1089/neu.2005.22.1428
15. Wessell, R. H.; Ahmed, S. M.; Menniti, F. S.; Dunbar, G. L.; Chase, T. N.; Oh, J. D. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats Neuropharmacology 2004, 47, 184-194 10.1016/j.neuropharm.2004.03.011
16. Tewes, B.; Frehland, B.; Schepmann, D.; Schmidtke, K.-U.; Winckler, T.; Wünsch, B. Design, synthesis, and biological evaluation of 3-benzazepin-1-ols as NR2B-selective NMDA receptor antagonists ChemMedChem 2010, 5, 687-695 10.1002/cmdc.201000005
17. Tewes, B.; Frehland, B.; Schepmann, D.; Schmidtke, K.-U.; Winckler, T.; Wünsch, B. Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols Bioorg. Med. Chem. 2010, 18, 8005-8015 10.1016/j.bmc.2010.09.026
18. Ordonez, M.; De La Cruz-Cordero, R.; Fernandez-Zertuche, M.; Munoz-Hernandez, M. A.; Garcia-Barradas, O. Diastereoselective reduction of dimethyl γ-[(N-p-toluenesulfonyl)amino]-β-ketophosphonates derived from amino acids Tetrahedron: Asymmetry 2004, 15, 3035-3043 10.1016/j.tetasy.2004.08.012
19. Chen, B. C.; Skoumbourdis, A. P.; Guo, P.; Bednarz, M. S.; Kocy, O. R.; Sundeen, J. E.; Vite, G. D. A facile method for the transformation of N-(tert-butoxycarbonyl) α-amino acids to N-unprotected α-amino methyl esters J. Org. Chem. 1999, 64, 9294-9296 10.1021/jo990311w
20. Swamy, C. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V. P. P. Mitsunobu and related reactions: advances and applications Chem. Rev. 2009, 109, 2551-2651 10.1021/cr800278z
21. Schläger, T.; Oberdorf, C.; Tewes, B.; Wünsch, B. Novel, one-pot procedure for the synthesis of 2-arylethanol derivatives Synthesis 2008, 2008, 1793-1797 10.1055/s-2008-1067021
22. Duhamel, L.; Fouquay, S.; Plaquevent, J.-C. Ligand exchange in asymmetric reactions of lithium enolates: application to the deracemization of α-aminoacids Tetrahedron Lett. 1986, 27, 4975-4978 10.1016/S0040-4039(00)85111-4
23. Tewes, B.; Frehland, B.; Fröhlich, R.; Wünsch, B. Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-methoxy-2-methyl-tetrahydro-3-benzazepin-1-ols. Acta Crystallogr., Sect. E, submitted 2015.
24. Tewes, B.; Frehland, B.; Fröhlich, R.; Wünsch, B. Relative configuration of 7-benzyloxy-2-methyl-3-tosyltetrahydro-3-benzazepin-1-ol for the elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists. Acta Crystallogr., Sect. E, submitted 2015.
25. Schepmann, D.; Frehland, B.; Lehmkuhl, K.; Tewes, B.; Wünsch, B. Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors J. Pharm. Biomed. Anal. 2010, 53, 603-608 10.1016/j.jpba.2010.04.014
26. Benner, A.; Bonifazi, A.; Shirataki, C.; Temme, L.; Schepmann, D.; Quaglia, W.; Shoji, O.; Watanabe, Y.; Daniliuc, C.; Wünsch, B. GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines ChemMedChem 2014, 9, 741-751 10.1002/cmdc.201300547
27. 1 receptor ligands J. Med. Chem. 2012, 55, 8953-8957 10.1021/jm301166m
28. Banerjee, A.; Schepmann, D.; Köhler, J.; Würthwein, E.-U.; Wünsch, B. Synthesis and SAR studies of chiral non-racemic dexoxadrol analogues as uncompetitive NMDA receptor antagonists Bioorg. Med. Chem. 2010, 18, 7855-7867 10.1016/j.bmc.2010.09.047
29. 1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones Bioorg. Med. Chem. 2013, 21, 1844-1856 10.1016/j.bmc.2013.01.038
30. Miyata, K.; Schepmann, D.; Wünsch, B. Synthesis and σ receptor affinity of regioisomeric spirocyclic furopyridines Eur. J. Med. Chem. 2014, 83, 709-716 10.1016/j.ejmech.2014.06.073
31. Hasebein, P.; Frehland, B.; Lehmkuhl, K.; Fröhlich, R.; Schepmann, D.; Wünsch, B. Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with α-substituted benzyl moiety in 5-position Org. Biomol. Chem. 2014, 12, 5407-5426 10.1039/c4ob00510d
32. Rook, Y.; Schmidtke, K.-U.; Gaube, F.; Schepmann, D.; Wünsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents J. Med. Chem. 2010, 53, 3611-3617 10.1021/jm1000024
33. Molecular Operating Environment (MOE), version 2012.10; Chemical Computing Group Inc. (1010 Sherbooke St. West, Suite No. 910, Montreal, QC, Canada, H3A 2R7), 2012.
34. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins: Struct., Funct., Genet. 2003, 52, 609-623 10.1002/prot.10465
35. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Swails, J.; Goetz, A. W.; Kolossváry, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wolf, R. M.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.-J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Salomon-Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER 12; University of California: San Francisco, CA, 2012.